Welcome to our dedicated page for Galectin Therapeutics SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galectin Therapeutics Inc. (NASDAQ: GALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer, Galectin Therapeutics uses these filings to report on its financial condition, clinical development activities, governance, and capital structure.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, including its focus on galectin-targeted therapeutics and the belapectin program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension. Current reports on Form 8-K highlight material events such as clinical data disclosures, new or supplemental lines of credit, changes to compensation arrangements, and the posting of updated corporate presentations.
Proxy materials, including definitive proxy statements on Schedule 14A, describe items submitted to stockholders, such as director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. These documents also outline aspects of corporate governance, board structure, and equity compensation.
Through this page, users can also monitor filings that relate to financing arrangements, including convertible promissory notes and warrants, which may affect Galectin Therapeutics’ capital resources and potential dilution. Real-time updates from EDGAR are paired with AI-powered summaries that highlight key points in lengthy reports, helping readers quickly identify information on topics such as the NAVIGATE trial, belapectin’s regulatory status, and risk factor disclosures.
For those researching GALT, this filings archive offers a structured view of the company’s official disclosures, from financial reporting to governance decisions, with tools to make complex regulatory documents easier to understand.
Galectin Therapeutics Inc director Henry Brem received a grant of stock options. The award covers 60,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $3.1600 per share, reported as a direct holding.
The options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. They vest 100% on December 31, 2026 and are scheduled to expire on March 12, 2036. Following this grant, Brem holds 60,000 stock options linked to Galectin common stock.
Galectin Therapeutics Inc. director Henry Brem filed an initial ownership report on Form 3 showing no common stock holdings. The filing indicates that, as of the reporting date, he is a director of the company but does not beneficially own any shares of common stock directly.
Galectin Therapeutics Inc. appointed Henry Brem, M.D. as an independent member of its Board of Directors, effective March 12, 2026. The company states he was not appointed under any arrangement with another person and has no related-party transactions requiring disclosure under Regulation S-K Item 404(a).
Dr. Brem is a renowned neurosurgeon-scientist and translational medicine leader, serving as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center. He helped develop image-guided neurosurgical techniques and localized drug delivery systems such as Gliadel wafers, has published more than 416 peer-reviewed papers, holds multiple patents, and has been continuously funded by the NIH for over four decades.
The Board believes his extensive medical, clinical development, and leadership background will support Galectin’s strategy as it advances its galectin-3 inhibitor belapectin for patients with MASH cirrhosis, portal hypertension, and certain cancers. He will receive compensation consistent with the company’s standard non-employee director program.
Galectin Therapeutics director Eldred Kary reported a small open‑market purchase of company stock. On 02/06/2026, Kary bought 300 shares of common stock at $2.70 per share, bringing his direct holdings to 65,682 shares.
The filing also lists 2,425 shares held as custodian for a minor child under the Uniform Transfers to Minors Act and 2,000 shares held in a special needs trust where he serves as trustee. Kary disclaims beneficial ownership of these indirect holdings.
Galectin Therapeutics Inc. reported an amended insider transaction for its President, CEO and director, Jack W. Callicutt. On January 16, 2026, he was granted a stock option to buy 91,000 shares of common stock at an exercise price of $3.04 per share under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
The option vests in four equal installments of 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027, and expires on January 16, 2036. Following this grant, Callicutt directly holds 91,000 derivative securities in the form of these options. This Form 4/A corrects the originally filed number of options previously reported on January 21, 2026.
Galectin Therapeutics director Carson Benjamin Sr reported an award of stock options under the company’s 2019 Omnibus Equity Incentive Plan. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share, recorded at a price of $0 for the grant itself. These options give the right to buy Galectin Therapeutics common stock and are held as direct ownership.
The options vest 100% on December 31, 2026, meaning they become fully exercisable on that date and remain outstanding until their expiration on January 16, 2036. Following this grant, Benjamin beneficially owns 60,000 derivative securities in the form of these stock options.
Galectin Therapeutics Inc. reported that its board of directors, following a recommendation from the compensation committee, approved cash retention bonuses for two senior executives. The Chief Medical Officer, Dr. Khurram Jamil, was granted a $300,000 cash retention bonus, and the Chief Financial Officer, Jack Callicutt, was granted a $150,000 cash retention bonus.
The bonuses will be paid in three equal installments on June 1, 2026, September 1, 2026 and December 1, 2026. Each officer must repay the full retention bonus if they voluntarily resign without good reason or are terminated for cause before December 31, 2026, consistent with their employment agreements. This structure is designed to encourage continuity in these key leadership roles through the end of 2026.
Galectin Therapeutics Inc. director Richard A. Zordani Jr. reported a grant of stock options on common shares. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share, issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
The options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Zordani beneficially owns 60,000 derivative securities directly in the form of these options, providing potential future ownership of the same number of Galectin common shares if exercised.
Galectin Therapeutics reported new equity awards to its Chief Medical Officer, Jamil Khurram. On January 16, 2026, Khurram received stock options covering 65,000 shares of common stock with an exercise price of $3.04 per share, expiring on January 16, 2036. These options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027 and December 31, 2027.
On the same date, Khurram was also granted 100,000 Restricted Stock Units under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. These RSUs vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement, and, if vested, convert into common stock on a one-for-one basis. Both awards are reported as directly owned.
Galectin Therapeutics director Kevin D. Freeman reported a new stock option award. On January 16, 2026, he was granted a stock option (right to buy) covering 60,000 shares of Galectin Therapeutics common stock at an exercise price of $3.04 per share.
The option was issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and will vest 100% on December 31, 2026. Following this grant, Freeman beneficially owns 60,000 derivative securities directly in the form of these stock options.